Mesaflor (Mesalazine)

Mesalazine works locally in the colon by inhibiting cyclooxygenase and lipoxygenase enzymes, scavenging free radicals, and modulating immune cell activity. This reduces the production of prostaglandins and leukotrienes, leading to decreased inflammation of the intestinal mucosa.

The specific dose and dosing schedule of Mesaflor are determined by the prescribing clinician based on the severity of disease, patient weight, and response to therapy. Only a qualified healthcare professional should set the appropriate regimen.

Safety data for mesalazine in pregnancy and lactation are limited, and the product is classified as pregnancy category unknown. Healthcare providers should weigh potential benefits against risks and consider alternative therapies when treating pregnant or nursing patients.

To request Mesaflor, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Mesaflor (mesalazine) is a first‑line topical therapy for mild to moderate ulcerative colitis, offering a favorable safety profile compared with systemic steroids or immunosuppressants. Unlike biologics, it acts locally in the colon and does not require injection, but it may be less effective in severe disease.

Mesaflor should be stored at room temperature, below 25 °C, in its original packaging. Keep the product away from moisture and direct sunlight to maintain stability and potency.

Mesaflor is supplied as a rectal formulation that is inserted into the rectum according to the prescriber's instructions. Proper administration ensures the medication contacts the inflamed mucosa for optimal therapeutic effect.

Serious risks include severe allergic reactions such as anaphylaxis, acute severe colitis or perforation, blood dyscrasias (e.g., neutropenia), renal impairment, and hepatotoxicity. Patients should be monitored regularly for these rare but potentially life‑threatening events.

Mesaflor is contraindicated in patients with known hypersensitivity to mesalazine or other aminosalicylates, and it should be avoided in individuals with severe sulfonamide allergy. Caution is also advised for patients with significant renal or hepatic dysfunction.